Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages

References

• Obermeyer F, Jankowiak M, Barkas N, et al. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science. 2022;376(6599):1327–1332.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022; 185(3):467-484.e15.
   PubMed Web of Science ®Google Scholar
• Torjesen I. COVID-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. Br Med J. 2021;375:n2943.
   PubMedGoogle Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422–2433.e13.
   PubMed Web of Science ®Google Scholar
• https://gisaid.org/.
   Google Scholar
• http://www.nhc.gov.cn/xcs/yqfkdt/202212/6f703313da6d4f07b6b450cc546b48c0.shtml.
   Google Scholar
• Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults. JAMA. 2021;326(1):35–45.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Boosters appear effective, but are they always needed? Lancet. 2021;398(10317):2055–2057.
   PubMedGoogle Scholar
• McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;375(6583):864–868.
   PubMed Web of Science ®Google Scholar
• Nutalai R, Zhou D, Tuekprakhon A, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell. 2022;185(12):2116–2131.e18.
   PubMed Web of Science ®Google Scholar
• https://outbreak.info/situation-reports?pango=BA.2.75.
   Google Scholar
• https://wsjk.tj.gov.cn/ZTZL1/ZTZL750/YQFKZL9424/FKDT1207/202201/t20220109_5774785.html.
   Google Scholar
• Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022;3(5):e348–e356.
   PubMedGoogle Scholar
• Suryawanshi RK, Chen IP, Ma T, et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature. 2022;607(7918):351–355.
   PubMedGoogle Scholar
• Park YJ, Pinto D, Walls AC, et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science. 2022;378(6620):619–627.
   PubMed Web of Science ®Google Scholar
• Quandt J, Muik A, Salisch N, et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022;7(75):eabq2427.
   PubMed Web of Science ®Google Scholar
• Tan CW, Lim BL, Young BE, et al. Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5. Lancet Microbe. 2022;S2666-5247(22):00220–8.
   Google Scholar
• Guo L, Zhang Q, Zhang C, et al. Association of school education With eyesight Among children and adolescents. JAMA Netw Open. 2022;5(4):e229545.
   PubMed Web of Science ®Google Scholar
• Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. Sci Transl Med. 2022;14(645):eabn8543.
   PubMed Web of Science ®Google Scholar
• Jia M, Wang X, Gong W, et al. Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study. J Med Virol. 2022;94(12):5746–5757.
   PubMed Web of Science ®Google Scholar
• Richardson SI, Moore PL. Targeting Fc effector function in vaccine design. Expert Opin Ther Targets. 2021;25(6):467–477.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5(520).
   PubMedGoogle Scholar
• Zohar T, Loos C, Fischinger S, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020;183(6):1508–1519.e12.
   PubMed Web of Science ®Google Scholar
• Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. Nat Rev Immunol. 2022;22(1):7–18.
   PubMed Web of Science ®Google Scholar
• Zuccarino-Catania GV, Sadanand S, Weisel FJ, et al. CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. Nat Immunol. 2014;15(7):631–637.
   PubMed Web of Science ®Google Scholar
• Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595(7867):426–431.
   PubMed Web of Science ®Google Scholar
• Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 2021;600(7889):517–522.
   PubMed Web of Science ®Google Scholar
• Gaebler C, Wang Z, Lorenzi JCC, et al. Road map for domesticating multi-genome rice using gene editing. Nature. 2021;591(7851):537–538.
   Google Scholar
• Park YJ, De Marco A, Starr TN, et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science. 2022;375(6579):449–454.
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Thomas PG. Count on US: T cells in SARS-CoV-2 infection and vaccination. Cell Rep Med. 2022;3(3):100562.
   PubMedGoogle Scholar